natgillin/translations-raw huggingface dataset:
The statistical significance of the measured effects is to be determined by calculating the standard deviation of the measured CO2 values (with and without the additional load) and by comparing the difference of the measured CO2 values (with and without the additional load) with the standard deviation.
Statistična pomembnost izmerjenih vplivov se določi z izračunom standardnega odmika izmerjenih vrednosti CO2 (z in brez dodatne obremenitve) in primerjavo razlike izmerjenih vrednosti CO2 (z in brez dodatne obremenitve) s standardnim odmikom.
The difference of the measured CO2 values is to be more than 3 times the standard deviation.
Razlika izmerjenih vrednosti CO2 mora biti več kot trikrat večja od standardnega odmika.
Electric energy consumption as determined in the Technical Guidelines for the preparation of applications for the approval of innovative technologies pursuant to Regulation (EC) No 443/2009, ‘the Technical Guidelines’.
Poraba električne energije, kot je določena v tehničnih smernicah za pripravo vlog za odobritev inovativnih tehnologij v skladu z Uredbo (ES) št. 443/2009, „tehnične smernice“.
The usage factors as determined in the Technical Guidelines.
Faktorji uporabe, kot so določeni v tehničnih smernicah.
OJ L 42, 15.2.2012, p. 1.
UL L 42, 15.2.2012, str. 1.
The manufacturer AUDI AG (the ‘Applicant’) submitted an application for the approval of an innovative technology on 29 August 2012.
Proizvajalec AUDI AG (v nadaljnjem besedilu: vlagatelj) je 29. avgusta 2012 predložil prošnjo za odobritev inovativne tehnologije.
The completeness of the application was assessed in accordance with Article 4 of Commission Implementing Regulation (EU) No 725/2011 of 25 July 2011 establishing a procedure for the approval and certification of innovative technologies for reducing CO2 emissions from passenger cars pursuant to Regulation (EC) No 443/2009 of the European Parliament and of the Council [2].
Popolnost prošnje je bila ocenjena v skladu s členom 4 Izvedbene uredbe Komisije (EU) št. 725/2011 z dne 25. julija 2011 o uvedbi postopka za odobritev in certificiranje inovativnih tehnologij za zmanjšanje emisij CO2 iz osebnih vozil v skladu z Uredbo (ES) št. 443/2009 Evropskega parlamenta in Sveta [2].
The Applicant provided the required information on 25 October 2012.
Vlagatelj je zahtevane podatke predložil 25. oktobra 2012.
The application was found to be complete and the period for the Commission’s assessment of the application started on the day following the date of official receipt of the complete information, i.e. 26 October 2012.
Prošnja je štela za popolno in obdobje, ki ga ima Komisija na voljo za oceno prošnje, je začelo teči na dan po uradnem prejemu popolnih podatkov, tj. 26. oktobra 2012.
The Applicant has provided data in support of halogen lighting as the technology with the highest market penetration in 2009.
Vlagatelj je predložil podatke, ki potrjujejo, da je tehnologija halogenskih žarometov v letu 2009 zabeležila največji prodor na trg.
The Commission notes that although other, more energy efficient, lighting technologies may have been in use within a limited segment of the car fleet, it is acknowledged that halogen lighting had the highest market penetration for the fleet as a whole.
Komisija priznava, da čeprav so se v omejenem segmentu voznega parka uporabljale druge, energetsko učinkovitejše svetlobne tehnologije, so glede na celotni vozni park halogenski žarometi imeli največji prodor na trg.
on subjecting 4-methylamphetamine to control measures
o uvedbi nadzornih ukrepov za 4-metilamfetamin
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances [1], and in particular Article 8(3) thereof,
ob upoštevanju Sklepa Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi [1] in zlasti člena 8(3) Sklepa,
A risk assessment report on 4-methylamphetamine was drawn up on the basis of Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction, and was subsequently received by the Commission on 29 November 2012.
Poročilo o oceni tveganja glede 4-metilamfetamina je bilo pripravljeno na podlagi člena 6 Sklepa 2005/387/PNZ na posebnem zasedanju razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami ter nato predloženo Komisiji 29. novembra 2012.
ethylamphetamine is a synthetic ring-methylated derivative of amphetamine which has predominantly been seized in powder and paste form in samples containing amphetamine and caffeine, but which has also appeared in tablet and liquid form.
etilamfetamin je sintetični derivat nadzorovane snovi amfetamin z metiliranim benzenovim obročem, ki se v večini primerov pojavlja v obliki prahu ali paste v vzorcih, ki vsebujejo amfetamin in kofein, pojavlja pa se tudi v tekoči obliki ali v obliki tablet.
It has emerged on the illicit amphetamine market where it is sold and used as the controlled drug, amphetamine.
Pojavil se je na nezakonitem trgu amfetamina, kjer se prodaja in uporablja kot amfetamin, ki je nadzorovana droga.
There has been one report of the substance being detected in a commercial product sold on the internet.
Eno poročilo navaja, da je bila snov odkrita v komercialen proizvodu, ki se prodaja na internetu.
The main chemical precursor for the synthesis of 4-methylamphetamine is 4-methylbenzyl methyl ketone (4-methyl-BMK), which appears to be commercially available on the internet and is not controlled under the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
Glavna kemična predhodna sestavina za sintetiziranje 4-metilamfetamina je 4-metilbenzil metil keton (4-metil-BMK), za katerega kaže, da je komercialno dostopen na spletu in ni na seznamu Konvencije Združenih narodov proti prepovedani trgovini z mamili in psihotropnimi substancami iz leta 1988.
The specific physical effects of 4-methylamphetamine have been rarely reported by users, since users are typically unaware that they have taken the substance.
Uporabniki 4-metilamfetamina redko navajajo njegove posebne fizične učinke, saj ponavadi ne vedo, da so zaužili to snov.
However, the few reports that are available suggest that it has stimulant-type effects.
Vendar maloštevilna dostopna poročila kažejo na to, da ima snov učinek, podoben poživilom.
Limited data available relating to humans suggest that the adverse effects of 4-methylamphetamine include hyperthermia, hypertension, anorexia, nausea, perspiration, gastric distress, coughing, vomiting, headache, palpitations, insomnia, paranoia, anxiety and depression.
Omejeni dostopni podatki, ki se nanašajo na ljudi, kažejo, da škodljivi učinki 4-metilamfetamina vključujejo hipertermijo, povišan krvni tlak, anoreksijo, slabost, znojenje, želodčne težave, kašelj, bruhanje, glavobol, palpitacije, nespečnost, paranojo, anksioznost in depresijo.
Current data is not sufficient to determine the relative dependence-producing potential of the substance.
Obstoječi podatki ne zadostujejo za ugotavljanje relativne potencialne odvisnosti od te snovi.
According to the limited data sources available, the acute toxicity of 4-methylamphetamine is similar to that of other stimulants.
Glede na omejene dostopne vire podatkov je akutna toksičnost 4-metilamfetamina podobna kot pri drugih poživilih.
Certain evidence suggests that a combination of 4-methylamphetamine with other substances, including amphetamine and caffeine, may result in a higher risk of overall enhanced toxicity.
Nekateri podatki kažejo, da lahko 4-metilamfetamin v kombinaciji z drugimi snovmi, kot sta amfetamin in kofein, poveča tveganje splošne toksičnosti.
There have been a total of 21 fatalities registered in four Member States where 4-methylamphetamine alone, or in combination with one or more substances, especially amphetamine, has been detected in post-mortem samples.
V obdukcijskih vzorcih 21 smrtnih primerov v štirih državah članicah je bila ugotovljena prisotnost 4-metilamfetamina ali kombinacije 4-metilamfetamina in ene ali več drugih snovi, predvsem amfetamina.
While it is not possible to determine with certainty from the information available the role of 4-methylamphetamine in those fatalities, in some cases the substance was the predominant drug detected, with levels comparable to those found in certain cases of death caused by the consumption of amphetamine.
Čeprav glede na dostopne informacije ni mogoče z gotovostjo določiti vloge 4-metilamfetamina v teh smrtnih primerih, je bila ta snov v nekaterih primerih prevladujoča ugotovljena droga, ugotovljene ravni pa so bile primerljive tistimi, ki so bile ugotovljene v nekaterih smrtnih primerih zaradi zaužitja amfetamina.
ethylamphetamine has been detected in 15 Member States, while one Member State has reported the manufacture of the substance on its territory.
etilamfetamin je bil zaznan v 15 državah članicah, medtem ko je ena država članica poročala o proizvodnji te snovi na njenem ozemlju.
Prevalence specific to 4-methylamphetamine is difficult to estimate.
Razširjenost 4-metilamfetamina je težko oceniti.
There is no information on specific demand for the substance from user groups and it is not commercially marketed through internet shops.
Informacije o specifičnem povpraševanju skupin uporabnikov po tej snovi niso na voljo, prav tako se snov ne trži prek spletnih trgovin.
The information available suggests that 4-methylamphetamine is produced and distributed by the same organised crime groups that are involved in the manufacture and trafficking of amphetamine.
Dostopne informacije kažejo, da 4-metilamfetamin proizvajajo in distribuirajo iste organizirane kriminalne združbe, ki sodelujejo v proizvodnji in preprodaji amfetamina.
ethylamphetamine has no known, established or acknowledged medical value or use in the Union and there is no marketing authorisation for the substance in the Union.
etilamfetamin nima znane, dokazane ali priznane zdravstvene vrednosti ali uporabe v Uniji in nima dovoljenja za promet v Uniji.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it may be used for any other legitimate purpose.
Poleg uporabe snovi za analitični referenčni standard in znanstvene raziskave ni drugih indicev, ki bi kazali, da jo je mogoče uporabljati v druge zakonite namene.
ethylamphetamine is not currently under assessment and has not been under assessment by the United Nations system.
etilamfetamin se trenutno ne ocenjuje in ni bil ocenjen v okviru sistema Združenih narodov.
The risk assessment report reveals that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance.
Poročilo o oceni tveganja kaže, da obstaja pomanjkanje dostopnih znanstvenih dokazov glede značilnosti in tveganj, povezanih s 4-metilamfetaminom, in opozarja, da so potrebne nadaljnje raziskave o splošnih zdravstvenih in socialnih tveganjih, povezanih s snovjo.
However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union. As a result of the health risks it poses, as documented in its detection in several reported fatalities, especially when used in combination with other substances; its strong resemblance in terms of appearance and effects with amphetamine;
Dostopni podatki pa vseeno predstavljajo zadosten razlog za uvedbo nadzornih ukrepov nad 4-metilamfetaminom v Uniji.
the fact that users may unknowingly consume the substance and its limited medical value or use, 4-methylamphetamine should be subjected to control measures across the Union.
Zdravstvena tveganja, ki jih 4-metilamfetamin predstavlja, kot so bila dokumentirana ob potrditvi njegove prisotnosti v več smrtnih primerih, zlasti kadar se uporablja v kombinaciji z drugimi snovmi; velika podobnost z amfetaminom v izgledu in učinkih; dejstvo, da ga uporabniki zaužijejo nevede, ter njegova omejena vrednost za uporabo v zdravstvu so vse razlogi, zaradi katerih bi bilo treba uvesti nadzorne ukrepe v Uniji.
Since 10 Member States already control 4-methylamphetamine, subjecting it to control measures across the Union may help avoid problems in cross-border law enforcement and judicial cooperation.
Ker je deset držav članic že uvedlo nadzorne ukrepe za 4-metilamfetamin, bi lahko z uvedbo nadzornih ukrepov v vsej Uniji pripomogli k odpravljanju težav pri čezmejnem kazenskem pregonu in sodelovanju pravosodnih organov.
Union-wide control measures may also help prevent 4-methylamphetamine developing as an alternative to amphetamine in the illicit drug markets,
Nadzorni ukrepi v vsej Uniji lahko pomagajo preprečevati razvoj 4-metilamfetamina kot nadomestka amfetamina na nezakonitem trgu z drogami –
The new psychoactive substance, 4-methylamphetamine, is hereby subjected to control measures across the Union.
Za novo psihoaktivno snov 4-metilamfetamin se uvedejo nadzorni ukrepi v vsej Uniji.
By 17 March 2014, Member States shall take the necessary measures, in accordance with their national law, to subject 4-methylamphetamine to control measures and criminal penalties, as provided for under their legislation complying with their obligations under the 1971 United Nations Convention on Psychotropic Substances.
Države članice do 17. marca 2014 sprejmejo potrebne ukrepe v skladu s svojim nacionalnim pravom, s katerimi za 4-metilamfetamin uvedejo nadzorne ukrepe in kazenske sankcije, kot jih določa njihova zakonodaja v skladu z njihovimi obveznostmi na podlagi Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971.
Eight Member States control the substance under drug control legislation by virtue of their obligations under the 1971 United Nations Convention on Psychotropic Substances.
Osem držav članic je v skladu s svojimi obveznostmi na podlagi Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971 v okviru zakonodaje na področju drog uvedlo nadzorne ukrepe za to snov.
Two other Member States apply the generic definition of phenethylamine in their national legislation to the product while one Member State controls it under its medicines legislation.
Dve drugi državi članici uporabljata za proizvod generično opredelitev za fetamin iz svojih nacionalnih zakonodaj, medtem ko ena država članica snov nadzoruje v skladu s svojo zakonodajo na področju zdravil.
rejecting a restriction of the authorisation of a biocidal product containing indoxacarb notified by Germany in accordance with Directive 98/8/EC of the European Parliament and of the Council
o zavrnitvi omejitve dovoljenja za biocidni pripravek, ki vsebuje indoksakarb, ki jo je Nemčija priglasila v skladu z Direktivo 98/8/ES Evropskega parlamenta in Sveta
(notified under document C(2013) 1366)
(notificirano pod dokumentarno številko C(2013) 1366)
Commission Directive 2009/87/EC of 29 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include indoxacarb as an active substance in Annex I thereto [2] added the active substance indoxacarb to products belonging to product-type 18:
Direktiva Komisije 2009/87/ES z dne 29. julija 2009 o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev indoksakarba kot aktivne snovi v Prilogo I k Direktivi [2] je dodala aktivno snov indoksakarb k pripravkom, ki spadajo v 18. vrsto izdelkov:
Insecticides, acaricides and products to control other arthropods, as defined in Annex V to Directive 98/8/EC.
insekticidi, akaricidi in pripravki za nadzor drugih členonožcev, kot je opredeljena v Prilogi V k Direktivi 98/8/ES.
Directive 2009/87/EC requires Member States to assess, for the purpose of granting product authorisation, any relevant use scenarios that have not been representatively addressed at the Union level risk assessment.
Direktiva 2009/87/ES določa, da države članice v postopku za izdajo dovoljenja za pripravek ocenijo vse ustrezne scenarije uporabe, ki niso bili reprezentativno obravnavani v oceni tveganja na ravni Unije.
The company DuPont de Nemours (Deutschland) GmbH (‘the applicant’) submitted an application to the United Kingdom for authorisation of a product containing indoxacarb (‘the contested product’) in accordance with Article 8 of Directive 98/8/EC.
Podjetje DuPont de Nemours (Nemčija) GmbH („predlagatelj“) je v skladu s členom 8 Direktive 98/8/ES pri pristojnih organih Združenega kraljestva vložilo vlogo za izdajo dovoljenja za pripravek, ki vsebuje indoksakarb („sporni pripravek“).
The names and reference numbers of the contested product in the Register for Biocidal Products (‘R4BP’) are indicated in the Annex to this Decision.
Imeni in referenčni številki spornega pripravka v registru biocidnih pripravkov („R4BP“) so navedeni v Prilogi k temu sklepu.
On 28 October 2011, the United Kingdom authorised the contested product for the control of ants.
Združeno kraljestvo je 28. oktobra 2011 izdalo dovoljenje za uporabo spornega pripravka za zaščito pred mravljami.
According to that authorisation, the product may be applied only in and around residential homes, industrial facilities, offices, warehouses, commercial kitchens, hospitals, schools, nursing homes, hotels, buses, trains, aircraft, retail and commercial establishments.
V skladu z navedenim dovoljenjem se lahko pripravek uporablja samo v in okoli stanovanjskih domov, industrijskih obratov, pisarn, skladišč, komercialnih kuhinj, bolnišnic, šol, domov za ostarele, hotelov, avtobusov, vlakov, letal ter maloprodajnih in trgovskih podjetij.
That authorisation further provides that the application of the contested product to food or feed areas of food or feed handling establishments may be made only as a crack and crevice treatment.
Navedeno dovoljenje še določa, da se sporni pripravek v prostorih obratov za ravnanje z živili in krmo lahko uporablja samo za obdelavo razpok in rež.
The authorisation set out that the product had to be labelled with the following instruction:
Dovoljenje določa, da je treba pripravek označiti z naslednjim navodilom:
‘Do not apply to areas where food/feed, food utensils or food processing surfaces may come into contact with, or be contaminated by the product’.
„Ne uporabljati v območjih, kjer lahko živila/krma, pribor ali površine za predelavo živil pridejo v stik s pripravkom ali jih pripravek onesnaži.“
On 21 December 2011, the applicant submitted a complete application to Germany for mutual recognition of the first authorisation in respect of the contested product.
Predlagatelj je 21. decembra 2011 pri pristojnih organih Nemčije vložil popolno vlogo za medsebojno priznanje prvega dovoljenja za sporni pripravek.
On 23 April 2012, Germany notified the Commission, the other Member States and the applicant of its proposal to restrict the first authorisation in accordance with Article 4(4) of Directive 98/8/EC by excluding food protection from the authorised intended uses of the contested product.
Nemčija je 23. aprila 2012 uradno obvestila Komisijo, druge države članice in predlagatelja o svojem predlogu za omejitev prvega dovoljenja v skladu s členom 4(4) Direktive 98/8/ES, tako da se iz predvidenih uporab spornega pripravka izključi zaščita živil.
As justification for the notification, Germany submitted that products used for food protection are covered, for this purpose, by Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC [3], and are hence excluded from the scope of Directive 98/8/EC if the protected food consists of plants or plant products within the meaning of Article 3(5) and (6) of Regulation (EC) No 1107/2009.
Nemčija je v utemeljitvi obvestila navedla, da so pripravki, ki se uporabljajo za zaščito živil, v ta namen zajeti v Uredbi (ES) št. 1107/2009 Evropskega parlamenta in Sveta z dne 21. oktobra 2009 o dajanju fitofarmacevtskih sredstev v promet in razveljavitvi direktiv Sveta 79/117/EGS in 91/414/EGS [3] ter tako izvzeti iz področja uporabe Direktive 98/8/ES, če zaščiteno živilo sestavljajo rastline ali rastlinski proizvodi v smislu člena 3(5) in (6) Uredbe (ES) št. 1107/2009.
The Commission invited the other Member States and the applicant to submit comments to the notification in writing within 90 days in accordance with Article 27(1) of Directive 98/8/EC.
Komisija je povabila druge države članice in predlagatelja, naj predložijo pisne pripombe na obvestilo v 90 dneh v skladu s členom 27(1) Direktive 98/8/ES.
Comments were submitted within that deadline by the United Kingdom, France and Spain.
Združeno kraljestvo, Francija in Španija so pripombe predložili v navedenem roku.
The notification was also discussed between Commission representatives, representatives of Member States’ Competent Authorities for biocidal products in the meeting of the Product Authorisation and Mutual Recognition Facilitation Group of 22-23 May 2012, where the applicant was present.
O obvestilu so razpravljali tudi predstavniki Komisije in predstavniki pristojnih organov držav članic za biocidne pripravke na srečanju Skupine za poenostavitev medsebojnega priznavanja in izdajo dovoljenj za pripravke, ki je potekalo od 22. do 23. maja 2012 in katerega se je udeležil tudi predlagatelj.
As it is undisputed that the contested product is covered by the definition of a biocidal product in Article 2(1)(a) of Directive 98/8/EC, it merely should be examined whether the product is nevertheless excluded from the scope of Directive 98/8/EC by virtue of Article 1(2)(r) of that Directive for the purpose of certain uses, in which case those particular uses would require an additional authorisation in accordance with Regulation (EC) No 1107/2009.
Ker ni sporno, da je sporni pripravek zajet v opredelitvi biocidnega pripravka iz člena 2(1)(a) Direktive 98/8/ES, bi bilo treba preučiti le, ali je pripravek kljub temu izvzet iz področja uporabe Direktive 98/8/ES v skladu s členom 1(2)(r) navedene direktive za nekatere uporabe, v tem primeru pa bi bilo treba za navedene posebne uporabe izdati dodatno dovoljenje v skladu z Uredbo (ES) št. 1107/2009.
It follows from Article 2(1)(a) of Regulation (EC) No 1107/2009 that that Regulation does not apply to products whose main purpose is considered to be hygiene rather than the protection of plants or plant products.
V skladu s členom 2(1)(a) Uredbe (ES) št. 1107/2009 se navedena uredba ne uporablja za proizvode, katerih glavni namen je higiena in ne varstvo rastlin ali rastlinskih proizvodov.
The contested product is, inter alia, intended for use as an insecticide against ants in commercial kitchens.
Sporni pripravek je med drugim namenjen za uporabo kot insekticid proti mravljam v komercialnih kuhinjah.
One of the intentions of such use can be the protection of plant products as defined in Article 3(6) of Regulation (EC) No 1107/2009, which can include food.
Eden od namenov take uporabe je lahko varstvo rastlinskih proizvodov, kot so določeni v členu 3(6) Uredbe (ES) št. 1107/2009, ki lahko vključujejo živila.
The contested product is also intended for a large number of other use areas, where it will not serve the purpose of protecting food consisting of plants or plant products.
Sporni pripravek je namenjen tudi za uporabo v številnih drugih prostorih, kjer ne bo prispeval k zaščiti živil iz rastlin ali rastlinskih proizvodov.
As the main purpose of the contested product is hygiene rather than the protection of plants or plant products, the product is not excluded from the scope of Directive 98/8/EC by virtue of Article 1(2)(r) of that Directive for the purpose of its use in commercial kitchens.
Ker je glavni namen spornega pripravka higiena in ne varstvo rastlin ali rastlinskih proizvodov, pripravek ni izključen iz področja uporabe Direktive 98/8/ES na podlagi člena 1(2)(r) navedene direktive za uporabo v komercialnih kuhinjah.
The Commission therefore considers that the restriction requested by Germany cannot be justified on the grounds put forward.
Zato Komisija meni, da omejitve, ki jo je zahtevala Nemčija, ni mogoče utemeljiti na podlagi predloženih razlogov.